IGBA Makes Access Pact With WHO
Promotes The Use Of Generics And Biosimilars
The World Health Organization has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the International Generic and Biosimilar Medicines Association to promote access to medicines.
You may also be interested in...
As biosimilars are added to the WHO’s list of essential drugs, an expert committee wants the global body to expand its pre-qualification program to cover more biosimilars.
In the final of three exclusive interviews, IGBA chair Jim Keon and secretary general Suzette Kox provide the latest update on global issues affecting the off-patent industries, including originator intellectual-property tactics in the form of the WIPO’s and IFPMA’s Pat-INFORMED database.
An online register of global patent information for medicines launched by the WIPO and brand industry body IFPMA serves as a tool for patent linkage, contains no mechanisms to ensure accuracy, and is inappropriate for a UN agency to endorse, according to the IGBA.